Yahoo
Taipei Exchange - Delayed Quote TWD

PharmaEngine, Inc. (4162.TWO)

57.30 -0.90 (-1.55%)
At close: 1:30:11 PM GMT+8
Chart Range Bar
Loading chart for 4162.TWO
  • Previous Close 58.20
  • Open 58.10
  • Bid 57.30 x --
  • Ask 57.40 x --
  • Day's Range 57.00 - 58.20
  • 52 Week Range 53.00 - 74.40
  • Volume 335,687
  • Avg. Volume 266,688
  • Market Cap (intraday) 8.233B
  • Beta (5Y Monthly) 0.11
  • PE Ratio (TTM) 15.28
  • EPS (TTM) 3.75
  • Earnings Date (est.) --
  • Forward Dividend & Yield 2.00 (3.44%)
  • Ex-Dividend Date Aug 17, 2026
  • 1y Target Est --

PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan. It offers ONIVYDE, a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. The company is also developing PEP07, a CHK1 inhibitor, which is in Phase 1 clinical trial for the treatment of hematological tumors and solid tumors. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan.

www.pharmaengine.com

45

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/2/2026, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .

YTD Return

4162.TWO
15.90%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
55.09%

1-Year Return

4162.TWO
16.73%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
59.10%

3-Year Return

4162.TWO
42.73%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
173.95%

5-Year Return

4162.TWO
18.67%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
163.21%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY25
Revenue 285.09M
Earnings 131.09M
Profit Margin 45.98%

Q1

FY25

Q2

FY25

Q3

FY25

Q4

FY25

0
100M
200M
0.0%
10.0%
20.0%
30.0%
40.0%
50.0%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    52.56%

  • Return on Assets (ttm)

    5.44%

  • Return on Equity (ttm)

    11.26%

  • Revenue (ttm)

    1.03B

  • Net Income Avi to Common (ttm)

    538.8M

  • Diluted EPS (ttm)

    3.75

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.07B

  • Total Debt/Equity (mrq)

    0.77%

  • Levered Free Cash Flow (ttm)

    -275.12M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: